Nalaganje...
Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
The incorporation of novel agents such as bortezomib and lenalidomide into initial therapy for multiple myeloma has improved the response rate of induction regimens. Also, these drugs are being increasingly used in the peri-transplant setting for transplant-eligible patients, and as part of consolid...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2013
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3819933/ https://ncbi.nlm.nih.gov/pubmed/24135408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.seminoncol.2013.07.007 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|